Biopsy Techniques for Musculoskeletal Tumors: Basic Principles and Specialized Techniques DOI Creative Commons
Andreas F. Mavrogenis,

Pavlos Altsitzioglou,

Shinji Tsukamoto

et al.

Current Oncology, Journal Year: 2024, Volume and Issue: 31(2), P. 900 - 917

Published: Feb. 5, 2024

Biopsy is a pivotal component in the diagnostic process of bone and soft tissue tumors. The objective to obtain adequate without compromising local tumor dissemination patient’s survival. This review explores contemporary principles practices musculoskeletal biopsies, emphasizing critical role accuracy while also delving into evolving landscape liquid biopsies as promising alternative field. A thorough literature search was done PubMed Google Scholar well physical books libraries summarize available biopsy techniques for tumors, discuss methods, risk factors, complications, emphasize challenges related oncology. Research articles that studied basic specialized patients were deemed eligible. Their advantages disadvantages, technical pathophysiological mechanisms, possible risks complications reviewed, summarized, discussed. An inadequately executed may hinder diagnosis subsequently impact treatment outcomes. All lesions should be approached with presumption malignancy until proven otherwise. Liquid have emerged potent non-invasive tool analyzing phenotype, progression, drug resistance guiding decisions sarcomas metastases. Despite advancements, several barriers remain including costs, scalability, reproducibility, isolation methods. It paramount orthopedic oncologists work together radiologists pathologists enhance diagnosis, patient outcomes, healthcare costs.

Language: Английский

Liquid biopsy: a step closer to transform diagnosis, prognosis and future of cancer treatments DOI Creative Commons
Saife N. Lone, Sabah Nisar, Tariq Masoodi

et al.

Molecular Cancer, Journal Year: 2022, Volume and Issue: 21(1)

Published: March 18, 2022

Over the past decade, invasive techniques for diagnosing and monitoring cancers are slowly being replaced by non-invasive methods such as liquid biopsy. Liquid biopsies have drastically revolutionized field of clinical oncology, offering ease in tumor sampling, continuous repeated devising personalized therapeutic regimens, screening resistance. consist isolating tumor-derived entities like circulating cells, DNA, extracellular vesicles, etc., present body fluids patients with cancer, followed an analysis genomic proteomic data contained within them. Methods isolation rapidly evolved over few years described review, thus providing greater details about characteristics progression, staging, heterogeneity, gene mutations, clonal evolution, etc. from cancer opened up newer avenues detection monitoring, treatment based on precision medicine, markers Though technology is still evolving, its nature promises to open new eras oncology. The purpose this review provide overview current methodologies involved their application detection, prognosis, outcomes.

Language: Английский

Citations

495
Liquid Biopsy for Advanced NSCLC: A Consensus Statement From the International Association for the Study of Lung Cancer DOI Creative Commons
Christian Rolfo, Philip C. Mack, Giorgio V. Scagliotti

et al.

Journal of Thoracic Oncology, Journal Year: 2021, Volume and Issue: 16(10), P. 1647 - 1662

Published: July 8, 2021

Language: Английский

Citations

446
Molecular Biomarkers in Cancer DOI Creative Commons
Virinder Kaur Sarhadi, Gemma Armengol

Biomolecules, Journal Year: 2022, Volume and Issue: 12(8), P. 1021 - 1021

Published: July 23, 2022

Molecular cancer biomarkers are any measurable molecular indicator of risk cancer, occurrence or patient outcome. They may include germline somatic genetic variants, epigenetic signatures, transcriptional changes, and proteomic signatures. These indicators based on biomolecules, such as nucleic acids proteins, that can be detected in samples obtained from tissues through tumor biopsy or, more easily non-invasively, blood (or serum plasma), saliva, buccal swabs, stool, urine, etc. Detection technologies have advanced tremendously over the last decades, including techniques next-generation sequencing, nanotechnology, methods to study circulating DNA/RNA exosomes. Clinical applications extensive. used tools for assessment, screening early detection accurate diagnosis, prognosis, prediction response therapy, surveillance monitoring response. Therefore, they help optimize making decisions clinical practice. Moreover, precision oncology is needed newly developed targeted therapies, functional only patients with specific mutations, identification these subsets patients. Improvement field is, however, overcome scientific challenge developing new greater sensitivity, specificity, positive predictive value.

Language: Английский

Citations

283
Liquid biopsy at the frontier of detection, prognosis and progression monitoring in colorectal cancer DOI Creative Commons
Hui Zhou, Liyong Zhu, Jun Song

et al.

Molecular Cancer, Journal Year: 2022, Volume and Issue: 21(1)

Published: March 25, 2022

Abstract Colorectal cancer (CRC) is one of the most common cancers worldwide and a leading cause carcinogenic death. To date, surgical resection regarded as gold standard by operator for clinical decisions. Because conventional tissue biopsy invasive only small sample can sometimes be obtained, it unable to represent heterogeneity tumor or dynamically monitor progression. Therefore, there an urgent need find new minimally noninvasive diagnostic strategy detect CRC at early stage recurrence. Over past years, concept called “liquid biopsy” has gained much attention. Liquid noninvasive, allowing repeated analysis real-time monitoring recurrence, metastasis therapeutic responses. With advanced development molecular techniques in CRC, circulating cells (CTCs), DNA (ctDNA), exosomes, tumor-educated platelet (TEP) detection have achieved interesting inspiring results prominent liquid markers. In this review, we focused on some applications CTCs, ctDNA, exosomes TEPs discuss promising future solve unmet needs patients.

Language: Английский

Citations

161
Clinical application and detection techniques of liquid biopsy in gastric cancer DOI Creative Commons
Shuo Ma, Meiling Zhou, Yanhua Xu

et al.

Molecular Cancer, Journal Year: 2023, Volume and Issue: 22(1)

Published: Jan. 11, 2023

Abstract Gastric cancer (GC) is one of the most common tumors worldwide and leading cause tumor-related mortality. Endoscopy serological tumor marker testing are currently main methods GC screening, treatment relies on surgical resection or chemotherapy. However, traditional examination more harmful to patients less sensitive accurate. A minimally invasive method respond early prognosis monitoring, efficacy, drug resistance situations urgently needed. As a result, liquid biopsy techniques have received much attention in clinical application GC. The non-invasive technique requires fewer samples, reproducible, can guide individualized patient by monitoring patients' molecular-level changes real-time. In this review, we introduced applications circulating cells, free DNA, non-coding RNAs, exosomes, proteins, which primary markers technology We also discuss current limitations future trends as applied technology.

Language: Английский

Citations

100
Overview and countermeasures of cancer burden in China DOI Open Access

Yian Wang,

Qijia Yan,

Chunmei Fan

et al.

Science China Life Sciences, Journal Year: 2023, Volume and Issue: 66(11), P. 2515 - 2526

Published: April 13, 2023

Language: Английский

Citations

83
PIK3CA Mutations as a Molecular Target for Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer DOI Creative Commons
Nicola Fusco, Umberto Malapelle, Matteo Fassan

et al.

Frontiers in Oncology, Journal Year: 2021, Volume and Issue: 11

Published: March 25, 2021

Despite the significant achievements in diagnosis and treatment of metastatic breast cancer (MBC), this condition remains substantially an incurable disease. In recent years, several clinical studies have aimed to identify novel molecular targets, therapeutic strategies, predictive biomarkers improve outcome women with MBC. Overall, ~40% hormone receptor (HR)

Language: Английский

Citations

104
Current Status of Circulating Tumor Cells, Circulating Tumor DNA, and Exosomes in Breast Cancer Liquid Biopsies DOI Open Access
Marta Tellez Gabriel, Erik Knutsen, Maria Perander

et al.

International Journal of Molecular Sciences, Journal Year: 2020, Volume and Issue: 21(24), P. 9457 - 9457

Published: Dec. 11, 2020

Breast cancer is the most common among women worldwide. Although five-, ten- and fifteen-year survival rates are good for breast patients diagnosed with early-stage disease, some cancers recur many years after completion of primary therapy. Tumor heterogeneity clonal evolution may lead to distant metastasis therapy resistance, which main causes cancer-associated deaths. In clinic today, imaging techniques like mammography tissue biopsies used diagnose cancer. Even though these methods important in diagnosis, they have limitations when it comes longitudinal monitoring residual disease treatment, progression, responses, recurrence. Over last few years, there has been an increasing interest diagnostic, prognostic, predictive potential circulating cancer-derived material acquired through liquid Thanks development sensitive devices platforms, a variety tumor-derived material, including cells (CTCs), DNA (ctDNA), biomolecules encapsulated extracellular vesicles, can now be extracted analyzed from body fluids. Here we will review recent studies on cancer, demonstrating clinical utility CTCs ctDNA. We also literature illustrating exosomal RNA proteins as future biomarkers Finally, discuss advantages perspectives this field management.

Language: Английский

Citations

80
Integrated approaches for precision oncology in colorectal cancer: The more you know, the better DOI
Pietro Andrei,

Paolo Battuello,

Gaia Grasso

et al.

Seminars in Cancer Biology, Journal Year: 2021, Volume and Issue: 84, P. 199 - 213

Published: April 13, 2021

Language: Английский

Citations

74
Non-small cell lung carcinoma (NSCLC): Implications on molecular pathology and advances in early diagnostics and therapeutics DOI Creative Commons
Hafiza Padinharayil, Jinsu Varghese,

Mithun Chacko John

et al.

Genes & Diseases, Journal Year: 2022, Volume and Issue: 10(3), P. 960 - 989

Published: Aug. 23, 2022

Continuous revision of the histologic and stage-wise classification lung cancer by World Health Organization (WHO) provides foundation for therapeutic advances promoting molecular targeted immunotherapies ensuring accurate diagnosis. Cancer epidemiologic data provide helpful information prevention, diagnosis, management, supporting health-care interventions. Global mortality projections from 2016 to 2060 show that will overtake ischemic heart diseases (IHD) as leading cause death (18.9 million) immediately after 2030, surpassing non-small cell (NSCLC), which accounts 85 percent cancers. The clinical stage at diagnosis is main prognostic factor in NSCLC therapies. Advanced early diagnostic methods are essential initial stages reduced compared advanced stages. Sophisticated approaches proper histological management have improved efficiency. Although immune checkpoint inhibitors (ICIs) therapies refined late-stage NSCLC, specificity sensitivity biomarkers should be focusing on prospective studies, followed their use tools. liquid biopsy candidates such circulating tumor cells (CTCs), cell-free DNA (cfDNA), educated platelets (TEP), extracellular vesicles (EVs) possess cancer-derived biomolecules aid tracing: driver mutations cancer, acquired resistance caused various generations agents, refractory disease, prognosis, surveillance.

Language: Английский

Citations

69